Method and system for evaluating the effect of verbascoside on radiation-induced lung injury based on acsl4 protein

Abstract

The application discloses a method and system for evaluating the effect of treating radiation-induced lung injury by verbascoside based on ACSL4 protein. The applicant first finds that verbascoside can play a role in treating radiation-induced lung injury by targeting ACSL4 protein and reducing the level of ACSL4 protein. Based on this, the applicant provides a method and system for evaluating the effect of treating radiation-induced lung injury by verbascoside based on the level of ACSL4 protein. The application provides further guidance for optimizing the treatment of radiation-induced lung injury by verbascoside and research, and has a wide application prospect in the clinic.

Description

Technical Field

[0001] This invention belongs to the field of healthcare informatics technology, specifically, it relates to a method and system for evaluating the efficacy of verbascoside in treating radiation-induced lung injury based on ACSL4 protein. Background Technology

[0002] Radiation-induced lung injury (RILI) is a complication that occurs after radiotherapy for thoracic malignancies (such as lung cancer and breast cancer). Its occurrence is closely related to the radiation dose, location, and extent of irradiation. High-dose or wide-area radiotherapy easily leads to pulmonary congestion, alveolar effusion, and fibrosis, eventually developing into irreversible interstitial pulmonary fibrosis. Patients typically experience dry cough, chest tightness, and progressive dyspnea 4-16 weeks after radiotherapy; some also experience low-grade fever unresponsive to antibiotic treatment. Chest X-rays show small patchy, blurred shadows in the irradiated area in the early stages, later revealing fibrotic features such as disordered lung markings and mediastinal shift, possibly accompanied by pleural thickening or a small amount of pleural effusion. Current clinical treatment focuses on adjusting the radiotherapy regimen. In the acute phase, symptomatic support is provided through oxygen therapy and cough suppressants. Severe cases require short-term use of glucocorticoids to relieve symptoms, but glucocorticoids have limited efficacy and significant side effects.

[0003] Acteoside (ACT), a natural product, possesses a wide range of biological activities, including anti-inflammatory, antibacterial, antiviral, antitumor, antioxidant, analgesic, neuroprotective, sexual function-enhancing, immunomodulatory, and cellular memory-enhancing effects. However, its specific therapeutic efficacy, target, and underlying molecular mechanisms for RILI remain unknown, thus hindering further guidance for optimizing the treatment and research of RILI with acteoside. Summary of the Invention

[0004] To overcome the shortcomings of existing technologies, the purpose of this invention is to provide a method for evaluating the efficacy of verbascoside in treating radiation-induced lung injury. This method can effectively evaluate the therapeutic effect of verbascoside on radiation-induced lung injury, thereby providing further guidance for optimizing the treatment and research of verbascoside on radiation-induced lung injury.

[0005] To achieve the above objectives, the present invention adopts the following technical solution: The first aspect of this invention provides a method for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein.

[0006] Furthermore, the method is performed by a computer, and the method includes the following steps: Obtain the expression data of ACSL4 protein in the sample to be tested; The obtained ACSL4 protein expression data are input into the efficacy evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Output the prediction results.

[0007] Furthermore, the efficacy evaluation model is constructed by inputting ACSL4 protein expression data from untreated radiation-induced lung injury patients and radiation-induced lung injury patients treated with verbascoside into a machine learning algorithm.

[0008] Furthermore, the machine learning algorithms include linear regression models, logistic regression models, linear discriminant analysis models, nearest neighbor models, perceptron models, support vector machine models, Naive Bayes models, AdaBoost models, GBDT models, XGBoost models, LightGBM models, CatBoost models, or random forest models.

[0009] Furthermore, the efficacy evaluation model obtains results based on the following criteria: when the expression data of the ACSL4 protein is below a threshold, a classification result is obtained indicating that verbascoside is effective in treating radiation-induced lung injury; when the expression data of the ACSL4 protein is above a threshold, a classification result is obtained indicating that verbascoside is ineffective in treating patients with radiation-induced lung injury.

[0010] A second aspect of the present invention provides a system for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein.

[0011] Furthermore, the system is used to implement the method described in the first aspect of the present invention.

[0012] Furthermore, the system includes: Data acquisition module: Acquires ACSL4 protein expression data in the sample to be tested; Therapeutic effect evaluation module: The obtained ACSL4 protein expression data is input into the therapeutic effect evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Results output module: Outputs the prediction results.

[0013] A third aspect of the present invention provides a computer device.

[0014] Furthermore, the device includes: a memory and a processor; the memory is used to store a computer program; the processor executes the computer program to implement the method described in the first aspect of the present invention.

[0015] A fourth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program, when executed by a processor, implements the method described in the first aspect of the present invention.

[0016] The fifth aspect of the present invention provides a computer program product, including a computer program that, when executed by a processor, implements the method described in the first aspect of the present invention.

[0017] The sixth aspect of this invention provides the use of reagents for detecting ACSL4 protein expression in the preparation of products for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury.

[0018] The seventh aspect of this invention provides the use of verbascoside in the preparation of a medicament for treating radiation-induced lung injury.

[0019] Furthermore, the dosage forms of the drug include gastrointestinal dosage forms and non-gastrointestinal dosage forms.

[0020] Furthermore, the gastrointestinal dosage forms include solutions, granules, tablets, capsules, suspensions, powders, sustained-release preparations, effervescent tablets, emulsions, syrups, drops, and chewable tablets.

[0021] Furthermore, the non-gastrointestinal dosage forms include injectable dosage forms, respiratory dosage forms, cavity dosage forms, mucosal dosage forms, and skin dosage forms.

[0022] Advantages and beneficial effects of the present invention: This invention is the first to discover that verbascoside exerts its therapeutic effect on radiation-induced lung injury by targeting the ACSL4 protein and reducing its levels. Based on this, the applicant provides a method and system for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein levels. This provides further guidance for optimizing the treatment and research of verbascoside on radiation-induced lung injury and helps guide clinicians in developing individualized treatment plans for patients. Attached Figure Description

[0023] Figure 1 A schematic diagram of the method flow provided by the present invention is shown; Figure 2 This image shows the resistance of ACT to radiation-induced structural and DNA damage in human alveolar organoids. Figure A shows the morphology of alveolar organoids under a bright-field microscope; Figure B shows HE staining of alveolar organoids; Figure C shows the morphological changes of alveolar organoids after exposure to 2 Gy radiation under a bright-field microscope; Figure D shows the diameter analysis of alveolar organoids; Figure E shows γ-H2AX immunofluorescence staining of alveolar organoids; and Figure F shows ROS immunofluorescence staining of alveolar organoids.

[0024] Figure 3The diagram illustrates the protective effect of ACT against radiation-induced lung injury in mice. Figure A shows a representative HE-stained lung tissue section from the control group; Figure B shows a representative HE-stained lung tissue section from the irradiated group (IR); Figure C shows a representative HE-stained lung tissue section from the IR + 25 mg / kg ACT group; Figure D shows a representative HE-stained lung tissue section from the IR + 50 mg / kg ACT group; Figure E shows a representative HE-stained lung tissue section from the IR + 100 mg / kg ACT group; Figure F shows a representative HE-stained lung tissue section from the IR + Lip-1 group; Figure G shows the total protein concentration in BALF; Figure H shows the total cell count in BALF; Figure I shows the protein level of IL-1β in BALF; Figure J shows the protein level of TNF-α in BALF; Figure K shows the mRNA expression level of IL-6 in lung tissue; Figure L shows the mRNA expression level of IL-1β in lung tissue; and Figure M shows the mRNA expression level of TNF-α in lung tissue.

[0025] Figure 4 The screening and validation of potential targets for ACT are shown in Figure A, which is a schematic diagram of the LiP-MS screening experiment; Figure B is a volcano plot of LiP-MS results for the ACT-treated group and the control group, showing the distribution of differentially expressed proteins; Figure C is a volcano plot of lung tissue proteomics analysis for the IR group and the control group, showing the distribution of differentially expressed proteins; Figure D is the intersection analysis of the top 10 changed proteins screened by LiP-MS and all significantly differentially expressed proteins in proteomics, identifying the common candidate target ACSL4; Figure E shows the detection of ACSL4 mRNA expression level in lung tissue; Figure F shows the detection of ACSL4 protein expression level in lung tissue by Western blotting; and Figure G shows the gray-scale quantitative analysis results of ACSL4 protein expression.

[0026] Figure 5 The diagram illustrates the binding of ACT to ACSL4 and its regulation of ACSL4 expression. Figure A shows the pull-down experiment using biotin-labeled ACT (Bio-ACT) to detect the binding of ACSL4 to ACT. Figure B shows the effect of ACT treatment on the thermal stability of ACSL4 protein using cell thermal displacement analysis (CETSA). Figure C shows the surface plasmon resonance (SPR) analysis of the binding kinetics of ACSL4 to ACT and the calculation of the equilibrium dissociation constant. Figure D shows the mRNA expression level of ACSL4 in mouse lung tissue. Figure E shows the Western blotting of ACSL4 protein expression levels in lung tissue. Figure F shows the quantitative results of ACSL4 protein expression levels in lung tissue. Figure G shows the changes in ACSL4 protein stability after treatment with ACT and the proteasome inhibitor MG132 in BEAS-2B cells. Detailed Implementation

[0027] To enable those skilled in the art to better understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings.

[0028] In some of the processes described in the specification, claims, and accompanying drawings of this invention, multiple operations appearing in a specific order are included. However, it should be clearly understood that these operations may not be executed in the order they appear herein, or may be executed in parallel. The operation numbers, such as S101, S102, etc., are merely used to distinguish different operations and do not represent any execution order. Furthermore, these processes may include more or fewer operations, and these operations may be executed sequentially or in parallel. It should be noted that the descriptions such as "first," "second," etc., in this document are used to distinguish different messages, devices, modules, etc., and do not represent a sequential order, nor do they limit "first" and "second" to different types.

[0029] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Unless otherwise specified in the following embodiments, conditions are performed according to conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used without specified manufacturers are all conventional products that can be purchased commercially.

[0030] Figure 1 This is a schematic flowchart of the method for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein provided by the present invention. Specifically, the method includes: 101: Obtain the expression data of ACSL4 protein in the sample to be tested; In this invention, the applicant discovered through research that verbascoside has a good protective effect against radiation-induced lung injury in both organoid and mouse models. Further research revealed that this protective effect is mediated through the ACSL4 protein. Verascoside can bind to the ACSL4 protein, and treatment with verbascoside reduces the expression level of the ACSL4 protein. This suggests that the ACSL4 protein can serve as a good biomarker for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury.

[0031] In this invention, the sample refers to a composition obtained from or derived from a patient / subject that contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical, and / or physiological characteristics. For example, a sample refers to any sample derived from a patient / subject that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell cultures, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, follicular fluid, semen, pancreatic juice, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tissue culture fluid, tissue extracts, homogenized tissue, cell extracts, and combinations thereof. In one embodiment of the invention, the sample is a lung tissue sample.

[0032] In this invention, the patient / subject can be human or non-human and can include, for example, animal strains or species used as a "model system" for research purposes. Similarly, the patient can include adults or adolescents (e.g., children). Furthermore, the patient can refer to any living organism that benefits from the verbascoside described herein, preferably a mammal (e.g., human or non-human). Examples of mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates (e.g., chimpanzees) and other apes and monkeys; livestock, such as cattle, horses, sheep, goats, pigs; domestic animals, such as rabbits, dogs, and cats; laboratory animals include rodents, such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, etc. In some embodiments of the invention, the patient / subject is preferably human, more preferably a human treated with verbascoside. In one embodiment of the invention, the patient is a mouse.

[0033] In some embodiments, ACSL4 protein expression data can be detected using methods well known in the art. Examples include mass spectrometry-based quantitative proteomics, immunoassays, Western blotting, spectrophotometry, enzymatic assays, ultraviolet assays, kinetic assays, electrochemical assays, colorimetric assays, turbidimetric assays, atomic absorption spectrometry, flow cytometry, mass flow cytometry, or any combination thereof. In one embodiment of the invention, Western blotting is used to obtain ACSL4 protein expression data.

[0034] In one embodiment of the present invention, we discovered that ACT has a therapeutic effect on RILI. To investigate the effect of ACT (MCE, HY-N0021) on RILI, we first constructed alveolar organoids derived from human induced pluripotent stem cells. Under a bright-field microscope, the constructed alveolar organoids exhibited typical cystic structures with clear boundaries ( Figure 2(A in the text). HE staining further confirmed the presence of obvious cavities within these alveolar organoid structures. Figure 2 (B in the original text). To evaluate the radiation therapy effect of ACT, we observed the morphological changes of alveolar organoids after exposure to 2 Gy radiation (X-rays). Compared with the radiation group, ACT-treated alveolar organoids maintained better structural integrity (B in the original text). Figure 2 C in the text). Quantitative analysis of alveolar organoid size showed that radiation led to a decrease in alveolar organoid diameter, but ACT treatment significantly maintained the size of the alveolar organoids. Figure 2 (D in the original text). We then assessed the levels of DNA damage and oxidative stress in the irradiated alveolar organoids. Immunofluorescence staining for the DNA double-strand break marker γ-H2AX showed the formation of prominent foci in the nuclei of the irradiated alveolar organoids. However, compared with the irradiated group, the intensity and number of γ-H2AX foci were significantly reduced in the ACT-treated group (D in the original text). Figure 2 The levels of reactive oxygen species (ROS) increased significantly after radiation exposure but decreased after ACT treatment. Figure 2 (F in the text).

[0035] To further verify the therapeutic effect of ACT on radiation-induced lung injury, we established a mouse model of radiation-induced lung injury and divided the animals into six groups: a control group, a simple irradiation group (IR group, 15 Gy, bilateral chest, single-dose irradiation, X-ray), three doses (25, 50, and 100 mg / kg) of IR+ACT intervention groups, and a positive control ferroptosis inhibitor (Lip-1)+IR group. After irradiation, the mice were administered the drugs intraperitoneally for 7 consecutive days, and lung tissue and bronchoalveolar lavage fluid (BALF) samples were collected. Lung tissue was embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE). HE results showed that the alveolar structure of the control group mice was basically normal. Compared with the control group, the IR group mice showed significant inflammatory cell infiltration, alveolar congestion, and alveolar wall thickening in their lung tissue. The ACT treatment groups at each dose and the Lip-1 positive control group significantly alleviated the above pathological changes, manifested as reduced inflammatory cell infiltration and decreased alveolar wall thickening. Figure 3 In the BALF analysis, compared with the IR group, the total protein concentration and total cell count in the BALF of mice in each ACT dose group were significantly reduced (AF). Figure 3 GK in BALF). ELISA detection of inflammatory factor levels in BALF revealed that both ACT and Lip-1 treatment significantly reduced the levels of IL-6 and TNF-α. Figure 3 In addition, RNA extraction and RT-qPCR analysis of lung tissue showed that, compared with the IR group, both ACT and Lip-1 treatments effectively inhibited the mRNA expression levels of IL-6, IL-1β, and TNF-α in lung tissue (IJ). Figure 3(KM in the middle).

[0036] In another embodiment of the invention, we demonstrated that ACT targets the ACSL4 protein. To further explore the mechanism by which ACT improves radiation-induced lung injury, we used limited protease digestion mass spectrometry (LiP-MS) to screen potential targets of ACT. Figure 4 (A) Based on fold change and T-test, the volcano plot showed that, compared with the control group, 2527 proteins were upregulated and 1858 proteins were downregulated in the ACT-treated group. Figure 4 (B in the text). Meanwhile, proteomic analysis of lung tissue from mice in the IR group and control group showed that 2139 proteins were upregulated and 2169 proteins were downregulated in the IR group. Figure 4 (C in the text). To further screen the targets of ACT, we performed an intersection analysis between the 10 proteins with the most significant changes in LiP-MS and all significantly differentially expressed proteins in proteomics, and found that ACSL4 was a common differentially expressed protein (C in the text). Figure 4 To verify the changes in ACSL4 expression in radiation-induced lung injury and its reliability as a potential target, we further examined the transcriptional and protein levels of ACSL4 in mouse lung tissue. The results showed that, compared with the control group, the mRNA level of ACSL4 in the lung tissue of mice in the IR group was significantly lower (D). Figure 4 E in the protein) and protein expression ( Figure 4 The levels of FG in the samples were significantly increased.

[0037] To further clarify the direct interaction between ACT and ACSL4, we first performed a pull-down experiment. After synthesizing biotin-tagged ACT (Bio-ACT) and co-incubating it with cell lysate, we detected ACSL4 binding to Bio-ACT, which could be competitively inhibited by free ACT. Figure 5 (A) Further analysis using cellular thermal displacement analysis (CETSA) revealed that, compared to the DMSO control group, the ACSL4 protein thermal stability was increased in the ACT-treated group (A). Figure 5 (B in the original text). Subsequently, surface plasmon resonance (SPR) analysis determined the equilibrium dissociation constant (KD) of ACSL4 and ACT to be 8.01 μM ( ). Figure 5 Based on this, we further investigated the regulatory role of ACT on ACSL4 expression. Compared with the IR group, ACT treatment did not affect the mRNA level of ACSL4 in lung tissue (C). Figure 5 (D in the text), but it can significantly reduce its protein expression level ( Figure 5To clarify the mechanism by which ACT downregulates ACSL4 protein, we treated cells with a combination of ACT and the proteasome inhibitor MG132. The results showed that MG132 could reverse ACT-induced ACSL4 protein degradation (EF). Figure 5 (G in the text). In summary, these data indicate that ACT exerts a protective effect against RILI by targeting the ACSL4 protein and downregulating its expression, suggesting that ACSL4 protein can serve as a good biomarker for evaluating the therapeutic effect of ACT on RILI.

[0038] 102: Input the obtained ACSL4 protein expression data into the efficacy evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Furthermore, the efficacy evaluation model is constructed by inputting ACSL4 protein expression data from untreated radiation-induced lung injury patients and radiation-induced lung injury patients treated with verbascoside into a machine learning algorithm.

[0039] Furthermore, the method for constructing the efficacy evaluation model is known to those skilled in the art, and the steps of associating ACSL4 protein expression data with a certain probability or risk can be implemented and realized in different ways.

[0040] Furthermore, the machine learning algorithms include linear regression models, logistic regression models, linear discriminant analysis models, nearest neighbor models, perceptron models, support vector machine models, Naive Bayes models, AdaBoost models, GBDT models, XGBoost models, LightGBM models, CatBoost models, or random forest models.

[0041] Furthermore, after constructing the evaluation model, the effectiveness of the model can be assessed using ROC curve analysis.

[0042] Furthermore, the efficacy evaluation model obtains results based on the following criteria: when the expression data of the ACSL4 protein is below a threshold, a classification result is obtained indicating that verbascoside is effective in treating radiation-induced lung injury; when the expression data of the ACSL4 protein is above a threshold, a classification result is obtained indicating that verbascoside is ineffective in treating patients with radiation-induced lung injury.

[0043] In some embodiments of the present invention, the preset threshold is a representative value of the radiation-induced lung injury patient sample, including but not limited to the maximum value, the third quartile, and the mean. In some preferred embodiments of the present invention, the population sample includes 20 or more samples, such as 30, 50, 80, 100, 150, 200, 300, 500, or more.

[0044] 103: Output the prediction results.

[0045] A second aspect of the present invention provides a system for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein.

[0046] Furthermore, the system is used to implement the method described in the first aspect of the present invention.

[0047] Furthermore, the system includes: Data acquisition module: Acquires ACSL4 protein expression data in the sample to be tested; Therapeutic effect evaluation module: The obtained ACSL4 protein expression data is input into the therapeutic effect evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Results output module: Outputs the prediction results.

[0048] Furthermore, the system may be a user's electronic device or a computer system remotely located relative to the electronic device.

[0049] A third aspect of the present invention provides a computer device.

[0050] Furthermore, the device includes: a memory and a processor; the memory is used to store a computer program; the processor executes the computer program to implement the method described in the first aspect of the present invention.

[0051] In some implementations, the processor may also be referred to as a CPU (Central Processing Unit). A processor may be an integrated circuit chip with signal processing capabilities. A processor can also be a general-purpose processor, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or other programmable logic devices, discrete gate or transistor logic devices, or discrete hardware components. A general-purpose processor can be a microprocessor or any conventional processor.

[0052] Furthermore, computer equipment can be mobile electronic devices.

[0053] It should be understood that the systems, apparatuses, and methods described in this invention can be implemented in other ways. For example, the apparatus embodiments described above are merely illustrative; for instance, the division of modules is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple modules or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the couplings or direct couplings or communication connections shown or discussed may be indirect couplings or communication connections through some interfaces, apparatuses, or modules, and may be electrical, mechanical, or other forms.

[0054] The modules described as separate components may or may not be physically separate. The components shown as modules may or may not be physical units; that is, they may be located in one place or distributed across multiple network units. Some or all of the units can be selected to achieve the purpose of this embodiment according to actual needs.

[0055] Furthermore, the functional modules in the various embodiments of the present invention can be integrated into one processing module, or each module can exist physically separately, or two or more modules can be integrated into one module. The integrated modules described above can be implemented in hardware or as software functional modules.

[0056] The above are merely embodiments of this application and do not limit the scope of this patent application. Any equivalent structural or procedural changes made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the scope of patent protection of this application.

Claims

1. A method for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein, characterized in that, The method is performed by a computer and includes the following steps: Obtain the expression data of ACSL4 protein in the sample to be tested; The obtained ACSL4 protein expression data are input into the efficacy evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Output the prediction results.

2. The method according to claim 1, characterized in that, The efficacy evaluation model was constructed by inputting ACSL4 protein expression data from untreated radiation-induced lung injury patients and radiation-induced lung injury patients treated with verbascoside into a machine learning algorithm.

3. The method according to claim 2, characterized in that, The machine learning algorithms include linear regression models, logistic regression models, linear discriminant analysis models, nearest neighbor models, perceptron models, support vector machine models, Naive Bayes models, AdaBoost models, GBDT models, XGBoost models, LightGBM models, CatBoost models, or random forest models.

4. The method according to claim 1, characterized in that, The efficacy evaluation model obtains results based on the following criteria: when the expression data of the ACSL4 protein is below a threshold, a classification result is obtained indicating that verbascoside is effective in treating radiation-induced lung injury; when the expression data of the ACSL4 protein is above a threshold, a classification result is obtained indicating that verbascoside is ineffective in treating patients with radiation-induced lung injury.

5. A system for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury based on ACSL4 protein, characterized in that, The system is used to implement the method according to any one of claims 1-4, the system comprising: Data acquisition module: Acquires ACSL4 protein expression data in the sample to be tested; Therapeutic effect evaluation module: The obtained ACSL4 protein expression data is input into the therapeutic effect evaluation model, which predicts the therapeutic effect of verbascoside on radiation-induced lung injury based on the ACSL4 protein expression data. Results output module: Outputs the prediction results.

6. A computer device, characterized in that, The device includes: a memory and a processor; the memory is used to store a computer program; the processor executes the computer program to implement the method of any one of claims 1-4.

7. A computer-readable storage medium, characterized in that, It stores a computer program thereon, which, when executed by a processor, implements the method as described in any one of claims 1-4.

8. A computer program product, comprising a computer program, characterized in that, When executed by a processor, the computer program implements the method described in any one of claims 1-4.

9. Application of reagents for detecting ACSL4 protein expression in the preparation of products for evaluating the therapeutic effect of verbascoside on radiation-induced lung injury.

10. Application of verbascoside in the preparation of drugs for treating radiation-induced lung injury.

Images